NCT05396859 2026-04-27Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaOHSU Knight Cancer InstitutePhase 1 Active not recruiting13 enrolled